<DOC>
	<DOCNO>NCT02316899</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety ASP0456 patient constipation predominant irritable bowel syndrome ( IBS-C ) .</brief_summary>
	<brief_title>Phase III Study Evaluate Efficacy Safety ASP0456 Patients With Constipation Predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>&lt; Period I ( double-blind period ) &gt; A multicenter , collaborative , double-blind , parallel comparative study conduct use IBS-C patient subject verify efficacy ASP0456 examine safety . After 2-week bowel habit observation period , subject satisfy primary enrollment criterion randomly allocate either ASP0456 group placebo group , orally administer drug placebo daily breakfast 12 week . &lt; Period II ( non-blind period ) &gt; A multicenter , collaborative , non-blind , non-controlled study conduct examine safety efficacy ASP0456 long-term administration IBS-C patient . After Period I , subject satisfy transfer criterion orally administer ASP0456 daily breakfast 40 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients abdominal pain discomfort repeatedly least 3 day per month 3 month screen examination associate least 2 follow 3 condition : ( 1 ) Improvement defecation ; ( 2 ) Onset associate change frequency stool ; ( 3 ) Onset associate change form ( appearance ) stool , symptom ( IBS symptom ) 6 month screen examination period Patients â‰¥ 25 % stools hard lumpy ( bowel movement occur without antidiarrheal , laxative , suppository enema ) &lt; 25 % loose ( mushy ) watery 3 month screen examination Patients pancolonoscopy contrast enema ( sigmoidoscopy ) onset IBS symptom organic change Patient history surgical resection stomach , gallbladder , small intestine , large intestine ( exclude resection appendicitis benign polyp ) Patient history current affection inflammatory bowel disease ( Crohn 's disease ulcerative colitis ) Patient history current affection ischemic colitis Patient currently affect infectious enteritis Patient currently affect hyperthyroidism hypothyroidism Patient currently affect active peptic ulcer In case female patient , one currently affect endometriosis uterine adenomyosis Patient high depression anxiety consider influence drug evaluation Patient history abuse drug alcohol within year consent acquisition , current abuse Patient use underwent use undergo drug/therapy/test prohibit combine 3 day start bowel habit observation period ( Day 17 ) thereafter Patient history current affection malignant tumor Patient currently affect serious cardiovascular disease , respiratory disease , kidney disease , hepatic disease , gastrointestinal disease ( exclude IBS ) , hemorrhagic disease , neural/mental disease Patient history drug allergy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>ASP0456</keyword>
	<keyword>constipation</keyword>
	<keyword>linaclotide</keyword>
	<keyword>irritable bowel syndrome ( IBS )</keyword>
</DOC>